[1]邹远妩,李芬,刘尚武.莫西沙星与左氧氟沙星对耐药性肺结核患者的疗效及痰菌定植的影响[J].现代检验医学杂志,2015,30(05):66-69.[doi:10.3969/j.issn.1671-7414.2015.05.020]
　ZOU Yuan-fu,LI Fen,LIU Shang-wu.Effect of Moxifloxacin and Levofloxacin in the Treatment of Drug Resistant Pulmonary Tuberculosis Patients and Its Influence for Sputum Bacterial Colonization[J].Journal of Modern Laboratory Medicine,2015,30(05):66-69.[doi:10.3969/j.issn.1671-7414.2015.05.020]
点击复制

莫西沙星与左氧氟沙星对耐药性肺结核患者的疗效及痰菌定植的影响()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
66-69
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Effect of Moxifloxacin and Levofloxacin in the Treatment of Drug Resistant Pulmonary Tuberculosis Patients and Its Influence for Sputum Bacterial Colonization
作者:
邹远妩1; 2; 李芬1; 刘尚武2
1.西安交通大学医学部第一附属医院，西安710061； 2.陕西省结核病防治院检验科，西安710100
Author(s):
ZOU Yuan-fu1; 2; LI Fen1; LIU Shang-wu2
1.the First Affiliated Hospital of Medicine College of Xi’an Jiaotong University，Xi’an 710061，China；2.Department of Clinical Laboratory，Shaanxi Provincial Tuberculosis Prevention Hospital，Xi’an 710100，China
关键词:
莫西沙星; 左氧氟沙星; 耐药性肺结核; 疗效; 痰菌定植
分类号:
R521；R446.5
DOI:
10.3969/j.issn.1671-7414.2015.05.020
文献标志码:
A
摘要:
目的研究莫西沙星与左氧氟沙星对耐药性肺结核患者的疗效及痰菌定植的影响。方法选择2012年6月～2014年5月经痰结核分枝杆菌药物敏感试验确定为耐药性肺结核的住院患者92例实施研究，根据数字法随机分成观察组(应用莫西沙星治疗)及对照组(应用左氧氟沙星治疗)各46例，治疗12个月后对比两组治疗后的整体疗效，在治疗不同时期(1，3，6及12个月)收集患者痰标本进行涂片抗酸染色获得痰菌定植转阴率，观察治疗后的病灶及空洞变化，以及两组药物不良反应。结果治疗满12个月观察组痰涂片阴性44例，阳性2例，阴转率95.65% ，对照组痰涂片阴性38例，阳性8例，阴转率82.61%；观察组治疗1个月～12个月的痰菌定植转阴率均分别显著高于对照组，差异均有统计学意义(χ2=4.449，4.423，6.571，4.039；均P＜0.05)；观察组的显效率是58.70%，总有效率是97.83%，均显著高于对照组的36.96%及80.43%，差异有统计学意义(χ2=4.356，7.180；均P＜0.05)。两组治疗后的病灶及空洞变化对比，差异无统计学意义(χ2=0.337，0.211，0.746，0.123；均P＞0.05)。观察组的总不良反应发生率为26.09%，与对照组的32.61%相比，差异无统计学意义(χ2=0.472；P＞0.05)。结论莫西沙星治疗耐药性肺结核患者具有较好的疗效，且能有效改善痰菌定植的状况，安全性较高，值得推荐。
Abstract:
ObjectiveTo analyze effect of levofloxacin and moxifloxacin in the treatment of drug resistant pulmonary tuberculosis patients and its influence for sputum bacterial colonization．MethodsChose 92 cases accepted treatment of drug-resistant pulmonary tuberculosis as research in the hospital from June 2012 to May 2014．According to the digital method，the were randomly divided into observation group (treated with moxifloxacin) and control group (treated with levofloxacin)，46 cases in each，12 months after treatment，compared the overall effect of the treatment between two groups，and at different times (1，3，6 and 12 months)，collected patients’ sputum specimens for acid fast staining staining to obtain sputum bacterial clearance rate．Observed the changes in the lesions and cavity and the drugs adverse reactions of the two groups．ResultsTreatment of 12 months，sputum smear negative of the observation group was 44 cases，positive was 2 cases，and the sputum negative conversion rates was 95.65%．Sputum smear negative of the observation group was 38 cases，positive was 8 cases，the sputum negative conversion rates was 82.61%．The effective rate of the observation group was 58.70%，the total effective rate was 97.83%，which was significantly higher than that of the control group’s 36.96% and 80.43%，and the difference was statistically significant (χ2=4.356，7.180；all P＜0.05)．Observation group treatment for 1 month to 12 months sputum bacteria　colonization negative rate were markedly higher than those in control group，the differences were statistically significant (χ2=4.449，4.423，6.571，4.039；all P＜0.05)．There was no significant difference between the two groups (χ2=0.337，0.211，0.746，0.123；all P＞0.05)．The total adverse reaction rate of the observation group was 26.09%，and the difference was not statistically significant (χ2=0.472，P＞0.05)．ConclusionMoxifloxacin in the treatment of drug-resistant pulmonary tuberculosis patients has good curative effect and can effectively improve the sputum bacteria colonization，has high security，worthy of recommendation．

参考文献/References:

［1］刘存旭．比较左氧氟沙星与莫西沙星治疗耐药性肺结核的疗效［J］．中国实用医刊，2015，42(10)：13-14． Liu CX．Curative effect of levofloxacin and moxiflo-xacin on drug resistant pulmonary tuberculosis［J］．Chinese Journal of Practical Medicine，2015，42(10)：13-14．
[2]Lee SH，Seo KA，Lee YM，et al．Low serum concentrations of moxifloxacin，prothionamide，and cycloserine on sputum conversion in multi-drug resistant TB［J］．Yonsei Med J，2015，56(4)：961-967．
[3]孟丹．莫西沙星与左氧氟沙星治疗耐药性肺结核的疗效比较［J］．中国农村卫生，2015，6(Total 60)：82． Meng D．The curative effect comparative of moxifloxacin and levofloxacin treatment of drug-resistant pulmonary tuberculosis［J］．China Rural Health，2015，6(Total 60)：82．
[4]Chen Z，Liang JQ，Wang JH，et al．Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis： A meta-analysis［J］．Tuberculosis，2015，95(4)：490-496．
[5]曾安津，董霞．莫西沙星与左氧氟沙星治疗耐药性肺结核的疗效比较［J］．临床肺科杂志，2012，17(11)：2036-2037． Zeng AJ，Dong X．The curative effect comparative of moxifloxacin and levofloxacin in the treatment of drug-resistant pulmonary tuberculosis［J］．Journal of Clinical Pulmonary Medicine，2012，17(11)：2036-2037．
[6]Dawson R， Diacon AH， Everitt D，et al．Efficiency and safety of the combination of moxifloxacin，pretomanid (PA-824)，and pyrazinamide during the first 8 weeks of antituberculosis treatment：a phase 2b，open-label，partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis［J］．Lancet，2015，385(9979)：1738-1747．
[7]Jo KW，Lee SD，Kim WS，et al．Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis［J］．Int J Tuberc Lung Dis，2014，18(1)：39-43．
[8]Koh WJ，Lee SH，Kang YA，et al．Comparison of le-vofloxacin versus moxifloxacin for multidrug-resistant tuberculosis［J］．Am J Respir Crit Care Med，2013，188(7)：858-864．
[9]Jawahar MS，Banurekha VV，Paramasivan CN，et al．Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients［J］．PLoS One，2013，8(7)：e67030．
[10]Jiang RH，Xu HB，Li L，et al．Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis： a retrospective study［J］．Int J Antimicrob Agents，2013，42(1)：36-41．
[11]Garazzino S，Scolfaro C，Raffaldi I，et al．Moxiflo-xacin for the treatment of pulmonary tuberculosis in children：a single center experience［J］．Pediatr Pulmonol，2014，49(4)：372-376．
[12]Manika K，Chatzika K，Zarogoulidis K，et al．Moxifloxacin in multidrug-resistant tuberculosis：is there any indication for therapeutic drug monitoring［J］．Eur Respir J，2012，40(4)：1051-1053．
[13]倪丽丽，景玲杰，杨景卉，等．结核分枝杆菌对氟喹诺酮类药物敏感性的实验研究［J］．现代检验医学杂志，2014，29(2)：84-86． Ni LL，Jing LJ，Yang JH，et al．Drng susceptibility testing of mycobacterium tuberculosis of fluoroquinolones［J］．Journal of Modern Laboratory Medicine，2014，29(2)：84-86．

备注/Memo

备注/Memo:
作者简介：邹远妩(1978-)，女，本科，主管检验师，研究方向：临床微生物，Tel：13991205155，029-85899099，E-mail：313680872@qq.com。 通讯作者：李芬，女，教授，博士生导师，E-mail:lifen418@126.com。
更新日期/Last Update: 1900-01-01